PB 63 of 2021

National Health (Continued Dispensing – Emergency Measures) Amendment Determination 2021 (No. 6)

I, NIKOLAI TSYGANOV, Assistant Secretary (Acting), Pricing and PBS Policy Branch, Technology Assessment and Access Division, Department of Health, and delegate of the Minister for Health and Aged Care, make the following determination.

Dated    29 June 2021

NIKOLAI TSYGANOV  

Contents

1 Name

2 Commencement

3 Authority

4  Schedule

Schedule 1—Amendments 2

National Health (Continued Dispensing - Emergency Measures) Determination 2020 2

1  Name

(1)  This instrument is the National Health (Continued Dispensing – Emergency Measures) Amendment Determination 2021 (No. 6).

(2)  This instrument may also be cited as PB 63 of 2021.

2  Commencement

(1)  Each provision of this instrument specified in column 1 of the table commences, or is taken to have commenced, in accordance with column 2 of the table. Any other statement in column 2 has effect according to its terms.

Note: This table relates only to the provisions of this instrument as originally made. It will not be amended to deal with any later amendments of this instrument.

 (2) Any information in column 3 of the table is not part of this instrument. Information may be inserted in this column, or information in it may be edited, in any published version of this instrument.

3  Authority

  This instrument is made under subsection 89A(3) of the National Health Act 1953.

4  Schedules

  Each instrument that is specified in a Schedule to this instrument is amended or repealed as set out in the applicable items in the Schedule concerned, and any other item in a Schedule to this instrument has effect according to its terms.

Schedule 1—Amendments

National Health (Continued Dispensing – Emergency Measures) Determination 2020

[1]           Schedule 1, entry for Captopril

omit:

[2]           Schedule 1, entry for Guselkumab

insert as first entry:

[3]           Schedule 1, after entry for Hydromorphone in the form Oral liquid containing hydromorphone hydrochloride 1 mg per mL, 200 mL

insert:

[4]           Schedule 1, after entry for Imipramine in the form Tablet containing imipramine hydrochloride 10 mg

insert:

[5]           Schedule 1, after entry for Indometacin in the form Suppository 100 mg

insert:

[6]           Schedule 1, omit entry for Interferon alfa‑2a

[7]           Schedule 1, after entry for Pancreatic extract in the form Capsule (containing enteric coated minimicrospheres) providing not less than 25,000 BP units of lipase activity

insert:

[8]           Schedule 1, entry for Progesterone

insert as first entry:

[9]           Schedule 1, after entry for Tofacitinib in the form Tablet 5 mg

insert: